Exact Sciences – Genomic Prostate Score ® (GPS™) Test and Adverse Pathology

Returning guest, Dr. Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences discusses a new study in “Urologic Oncology: Seminars and Original Investigations” that validates adverse pathology as a predictor of prostate cancer outcomes in clinically low-risk patients. This news supports the utility of the Oncotype DX GPS™ test to manage treatment decisions by showing that the combined risk of adverse pathology is more strongly associated with worse long-term outcomes than the separate risks for high-grade disease and non-organ confined disease alone. 

Rick Baehner, M.D., is the Chief Medical Officer of Precision Oncology at Exact Sciences which is focused on improving the quality of treatment decisions for cancer patients. He and his colleagues have worked together with leading global oncology clinical research groups to use new molecular diagnostic methods and rigorous clinical studies to develop and commercialize the Oncotype DX ® breast cancer, colon cancer, prostate cancer and liquid biopsy assays.

Dr. Baehner is also a faculty member at the University of California, San Francisco and has been a leader in breast pathology and cytopathology for more than a decade.